Announcement by Sumitomo Pharma America, Inc. (SMPA) of the First Patient Receiving a Transplant in the Phase 1/2 Study of an iPSC-Derived Retinal Sheet Therapy for Retinitis Pigmentosa in the U.S.

Research and Development

2026.08.13

SMPA announced on 12 August, 2026, that the first patient has undergone implantation in a U.S. Phase 1/2 clini…

Development of the Regenerative Medicine Product “AMCHEPRY®” Receives the 10th Japan Bioindustry Award

Research and Development

2026.07.15

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; “Sumitomo Pharma”) and R…

Announcement by Sumitomo Pharma America, Inc. (SMPA) Regarding the U.S. Orphan Drug Designation for an Allogeneic iPS cell-derived Retinal Sheet (3-dimensional retina) as a Treatment for Retinitis Pigmentosa

Research and Development

2026.03.24

SMPA announced on 23 March 2026 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Desig…

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY®” in Japan

Research and Development

2026.03.06

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; “Sumitomo Pharma”) and R…

Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan

Research and Development

2025.12.24

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; “Sumitomo Pharma”) and RACTHERACo., Ltd. (Head Office: C…

RACTHERA Inc. Corporate Website Launch Announcement

Company

2025.12.24

RACTHERA Inc. has launched its corporate website. We are a joint venture established through joint investment …